Keyword: Advent International
Private equity investor Advent International has picked up another piece of Sanofi that the French drugmaker is shedding.
GSK is grouping some non-core consumer products into three portfolios for sell-offs so it can win EU antitrust clearance for its Pfizer deal.
Sanofi and Advent have ironed out the details on a €1.9 billion sale of Sanofi's European generics unit, dubbed Zentiva.
Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."
Other bidders may have dropped out of an auction for Sanofi's European generics unit, but that doesn't mean it hasn't found a buyer.
In the wake of last week's canceled buyout, Stada's CEO and CFO have left the company, and new buyout talk has already sprung up.
Pfizer is accepting a tiny payment in return for relinquishing its stake in a faltering generics joint venture in Brazil.
German drugmaker Stada has announced plans to sell itself for €5.32 billion ($5.63 billion) shortly after weighing a $3.7 billion private equity takeout.
Amid a flurry of deal action for German drugmaker Stada, local media report that CEO Matthias Wiedenfels was targeted in a spying operation.
Buyout target Stada is rolling out cost-cutting measures and new guidance in an attempt to bring in larger bids.